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Reply
We appreciate Dr Verdant’s comments regarding our recent
article describing our experience with endovascular stent graft
repair of thoracic aortic aneurysms. There are a few comments we
would specifically like to address.
Dr Verdant states that we have clearly established the “poor
performance” of this technology, implying that the 33% mortality
at 40 months is aneurysm related. This is incorrect. As is clearly
stated in the article, 6 deaths were attributable to aneurysm-related
causes. The rest were from underlying comorbid medical illnesses.
With regards to the Type I endoleak rate, we have adopted a more
liberal approach to performing combined open and endovascular
repairs of thoracic aneurysms. Since the time of publication, we
have enrolled 18 more patients in our protocol, all using the Talent
device. Of these 18 patients, 7 had their stent graft as the second
stage of an elephant trunk repair. The results in these 18 patients
have been heartening. We achieved primary clinical success in 17;
in 1 patient, we were unable to deliver the device due to aortic
tortuosity. There were 2 mortalities in this cohort: 1 from infective
endocarditis which was present at the time of initial presentation,
and 1 from a ruptured infrarenal aneurysm. There were no major
procedure-related morbidities. There were no thoracic aneurysm–
or device-related deaths. There were no Type I or Type III
endoleaks.
We agree wholeheartedly with Dr Verdant’s sentiment that
these cases should be done in “highly specialized centers for aortic
surgery equipped with fully trained personnel and optimal meth-
ods of organ protection.” As a matter of fact, our multidisciplinary
team includes a group of cardiac surgeons with extensive experi-
ence in open thoracic aneurysm repair. The cases are reviewed as a
group, and the most appropriate course of therapy is decided upon.
Thoracic stent-graft technology is still very much in evolution,
and we recognize that it is still investigational. One of the goals of
our article was to bring to light the limitations of current technol-
ogy. However, one should be careful not to “throw out the baby
with the bathwater.” Dr Verdant states that any “technique of graft
insertion in which the adventitia is . . . excluded is doomed to
failure.” Clinical data clearly suggests otherwise. The evolving
experience with endovascular stent-graft repair of infrarenal ab-
dominal aortic aneurysms has shown us that endoluminal aneu-
rysm exclusion results in a durable and safe repair with decreased
morbidity in properly selected patients.1 We feel confident that
with improvements in patient selection, device delivery systems,
and stent-graft design, the same will be true for the thoracic aorta.
The analogy can be made to the evolution of the prosthetic
cardiac valve, a process that took more than 15 years. Think how
many people would not be alive today if the development process
had been abandoned because of early failures.
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Regarding “Randomized trial and local biological
effect of autologous platelets used as adjuvant therapy
for chronic venous leg ulcers”
We read with the greatest interest the paper recently published
by Senet et al (J Vasc Surg 2003;38:1342-8). We appreciated the
very professional way used to assess the in vivo and in vitro capacity
(or incapacity) for platelet concentrate to enhance healing of
chronic ulcers. However, their results are quite different from our
own.
We have used platelet gel in clinical practice since 2000.
Platelet gel is a semisolid product obtained by activating autolo-
gous platelet concentrates with an autologous thrombin precursor
obtained by recalcification of autologous plasma. We obtain autol-
ogous platelets by processing either tubes or blood bag–collected
blood according to the necessary platelet gel volume or patient
conditions. Fresh or cryopreserved platelets are interchangeably
used, platelet-derived growth factors being quite thermostable.1,2
Whichever the blood collection system—tube differential centrif-
ugation or buffy-coat derived platelets as described by Senet et
al—we resuspend platelets in autologous plasma at the final con-
centration of 1-2 10/mL. So two main differences exist between
Senet et al’s platelet preparation and ours: we resuspend platelets in
fresh autologous plasma instead of saline, and the final platelet
concentration in our product actually is two to four times more
concentrated.
Senet et al treated lesions with 107 platelets/cm2. We treat
lesions with platelet gel containing 0.3-0.4  10 platelets/cm,
which is approximately 40 times the platelet amount used by Senet
and colleagues. Finally, we dress ulcerative lesions once per week
instead of 3 times per week.
In vitro experiments have shown that proliferation of human
fibroblast is strongly enhanced by addition of crude platelet lysate
to the culture medium. Proliferation rate is dose and time depen-
dent. The proliferation level is maximal between culture day 7 and
11. In our in-vitro experiments the proliferation rate was clearly
dose dependent, from 5% to 30% (platelet lysate/culture medium,
v/v considering 0% no addition of platelet lysate) (Fig). All of this
taken together may explain why Senet and colleagues obtained
negligible results in vivo and in vitro, in spite their highly profes-
sional experimental trial, while in our hands more than 85% of
patients respond to treatment and the healing time is roughly
halved.
We are confident that Senet and colleagues did not obtain
noticeable results either in vivo or in vitro simply because they used
platelet concentrates under the limit of biological activity of
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growth factors therein contained. Similarly, we are confident that if
the experiments were repeated using higher platelet doses, their
findings would completely different. Finally, we wonder about the
exceedingly broad spectrum of exclusion criteria. Many of our
patients are elderly, are diabetic, may have coexisting diseases
including rheumatic diseases, may have exposed bone or tendon,
or may have very limited mobility. Actually, it is these kinds of
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We thank Dr Piero Borzini and colleagues for their interest in
our article, and we want to answer to their remarks. Borzini et al
discuss three points: (1) the platelet concentration of the product
tested for its wound healing adjuvant effect and the quantity of
platelets applied on the wound to treat, (2) the platelet product
used for cutaneous wound healing, and (3) the choice of chronic
cutaneous lesions to treat with a platelet adjuvant therapy. Con-
cerning the first point, we applied a lower quantity of platelets than
Borzini et al (10 vs 0.2-0.4 10 platelets/cm) from a preparation
at 5  10 platelets/mL (vs 1-2  10/mL). We observed in vitro
biological effects induced by platelet lysates, with a maximal effect
observed at 10 platelets/mL on normal dermal fibroblasts at an
early passage, grown in monolayer as well as in a tridimensionnal
matrix. The observed effects concerned cell growth as well as
stimulation by platelets of fibroblast cytokine production. The
Figure presents the fibroblast growth curves in the presence of
three different platelet concentrations, 10 platelets /mL corre-
sponding to 10% platelets in the letter of Borzini et al. The cell
growth was tested by an MTT test as previously reported by others
and by us.1 We point out that a significant proliferative effect is
already observed at day 3 with 5  10 platelets/mL.
Concerning the second point, the platelet preparation is in-
deed a crucial point, as is discussed in our article. Borzini et al used
a platelet gel obtained by thrombin activation of platelet-rich
plasma. This kind of preparation contains platelet growth factors
and adhesive proteins but also lipid mediators and a fibrin matrix
that mimics the matrix of the first steps of cutaneous wound
healing.2
Then, we arrive at the third point. Evaluation of the healing
effect is the key point in clinical trials on wound healing. Many
patients may improve with an adjuvant local treatment as a dress-
ing, only because they are included in a trial, with good local
wound care and adequate compression therapy. Thus, concerning
venous ulcers, it is absolutely necessary to test therapeutic hypoth-
eses in trials with a control group, and to take the rate and time to
complete healing at end points of the study. Therefore, to obtain
homogeneous comparable groups of patients, we excluded pa-
tients who presented with wounds that were not only from venous
origin, such as patients with an uncontrolled systemic disease, as
well as patients with bad local conditions such as bone exposition.
It is important to emphasize that Stacey at al3 observed no platelet
adjuvant effect for the closure of venous leg ulcers, using sonni-
cated platelets in phosphate buffer saline at 3  10/cm. As
discussed in our article, diabetic foot ulcers, but not venous leg
ulcers, appear today to be good candidates for an adjuvant treat-
ment with platelet products or recombinant growth factors. To our
knowledge, no clinical trial has tested the therapeutic adjuvant
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Proliferative effect of PLTE on cultured fibroblasts.
Fibroblast growth curves in presence of platelets.
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